#ESMO23 dispatch: What to know about the HER3 ADC that got Merck to pay $2B cash

MADRID — Among the three an­ti­body-drug con­ju­gates from Mer­ck’s deal with Dai­ichi Sankyo, pa­tri­tum­ab derux­te­can takes up the largest por­tion of the $4 bil­lion up­front at $2 bil­lion. It is al­so the most ad­vanced, with a BLA slat­ed for 2024. To learn more about the HER3-tar­get­ing as­set, End­points News spoke to pa­tri­tum­ab in­ves­ti­ga­tor Pasi Jänne on the side­lines of the Eu­ro­pean So­ci­ety for Med­ical On­col­o­gy in Madrid.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.